


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Original): Compounds of general formula I



in which

X stands for CH or N,

W stands for hydrogen or fluorine,

A, B, D,

E and Q, in each case independently of one another, stand for a nitrogen or carbon

atom, whereby only a maximum of two nitrogen atoms can be present in the ring,

R¹ stands for aryl or heteroaryl, which optionally can be substituted in one or more places in the same way or differently with halogen, hydroxy, C₁-C₁₂-alkyl, C₃-C₆-cycloalkyl, C₃-C₆-alkenyl, C₂-C₆-alkinyl, aralkyloxy, C₁-C₁₂-alkoxy, halo-C₁-C₆-alkyl, cyano-C₁-C₆-alkyl or with the group =O, -SO₂R⁶ or -OR⁵, whereby the C₁-C₆-alkyl optionally also can be substituted with the group -OR⁵ or -NR⁹R¹⁰,

Y and Z, in each case independently of one another, stand for a bond or for the

group =CO, =CS or =SO₂,

R² and R³, independently of one another, stand for hydrogen or for the group

-CONR⁹R¹⁰, -SO²R⁶, -COR¹¹, -COC₁-C₆-alkyl, -CO-C₁-C₆-alkyl-R¹¹,

-NR⁹R¹⁰ or for C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl, C₃-C₆-cycloalkenyl, aryl or

heteroaryl that is optionally substituted in one or more places in the same way or

differently with halogen, cyano, C₁-C₁₂-alkyl, C₁-C₁₂-alkoxy, hydroxy-C₁-C₆-

alkyl, halo-C₁-C₆-alkyl or with the group -NR⁷R⁸, -OR⁵,

-C₁-C₆-alkyl-OR⁵, -SR⁴, -SOR⁴ or -SO₂R⁶, or

R², R³, Y

and Z together with the nitrogen atom form a 3- to 8-membered saturated or unsaturated

ring, which optionally can contain additional heteroatoms in the ring and

optionally can be substituted in one or more places in the same way or differently

with halogen, cyano, C₁-C₁₂-alkyl, C₁-C₁₂-alkoxy, halo-C₁-C₆-alkyl, hydroxy-C₁-

C₆-alkyl, or with the group =O, -OR⁵, -SR⁴, -SOR⁴ or -SO₂R⁶,

R⁴ stands for C₁-C₁₂-alkyl, aryl or heteroaryl,

R⁵ stands for hydrogen, C₁-C₁₂-alkyl, C₃-C₁₀-cycloalkyl, C₁-C₁₂-alkoxy, halo-

C₁-C₁₂-alkyl, or halo-C₃-C₆-cycloalkyl,

R⁶ stands for hydrogen, C₁-C₁₂-alkyl, halo-C₁-C₆-alkyl, aryl or heteroaryl, or

for the group -NR⁹R¹⁰, whereby the aryl or heteroaryl itself optionally can

be substituted in one or more places in the same way or differently with

C₁-C₁₂-alkyl, C₁-C₆-alkoxy, halogen or halo-C₁-C₆-alkoxy,

R⁷ and R⁸, independently of one another, stand for hydrogen or C₁-C₁₂-alkyl,

R⁹ and R¹⁰, independently of one another, stand for hydrogen, C₁-C₆-alkyl,

C₂-C₆-alkenyl, aryl, C₃-C₈-cycloalkyl or for the group –CONR⁷R⁸, or for

C₁-C₁₂-alkyl that is optionally substituted in one or more places in the same way

or differently with aryl, morpholino, hydroxy, halogen, C₁-C₁₂-alkoxy, or for the

group –NR⁷R⁸, whereby the aryl itself optionally can be substituted in one or more

places in the same way or differently with C₁-C₆-alkoxy or halo-C₁-C₆-alkyl, or

R⁹ and R¹⁰ together form a 5- to 8-membered ring that can contain additional

heteroatoms, and

R¹¹ stands for C₁-C₆-alkyl, C₁-C₆-alkoxy, hydroxy-C₁-C₆-alkyl, hydroxy-C₁-C₆-

alkoxy, C₃-C₆-cycloalkyl, phenyl, pyridyl, biphenyl or naphthyl, whereby the

phenyl itself can be substituted in one or more places in the same way or

differently with C₁-C₆-alkyl, or halo-C₁-C₆-alkyl, as well as isomers,

diastereomers, tautomers and salts thereof.

Claim 2 (Original): Compounds of general formula I, according to claim 1, in which

X stands for CH,

W stands for hydrogen,

A, B, D,

E and Q as a ring together stand for pyridyl,

R¹ stands for aryl or heteroaryl, which optionally can be substituted in one or more places in the same way or differently with halogen, hydroxy, C₁-C₆-alkyl,

C₃-C₆-cycloalkyl, C₄-C₆-alkenyl, C₂-C₆-alkinyl, aralkyloxy, C₁-C₆-alkoxy, halo-C₁-C₆-alkyl, cyano-C₁-C₆-alkyl, or with the group =O, -SO₂R⁶ or -OR⁵, whereby C₁-C₆-alkyl optionally also can be substituted with the group -OR⁵ or -NR⁹R¹⁰,

Y and Z, in each case independently of one another, stand for a bond,

R² and R³, independently of one another, stand for hydrogen or for the group

-CONR⁹R¹⁰, -SO₂R⁶, -COR¹¹, -COC₁-C₆-alkyl, -CO-C₁-C₆-alkyl-R¹¹, -NR⁹R¹⁰ or for C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₆-cycloalkenyl, aryl or heteroaryl that is optionally substituted in one or more places in the same way or differently with halogen, cyano, C₁-C₆-alkyl, C₁-C₆-alkoxy, hydroxy-C₁-C₆-alkyl, halo-C₁-C₆-alkyl or with the group -NR⁷R⁸, -OR⁵, -C₁-C₆-alkyl-OR⁵, -SR⁴, -SOR⁴ or -SO₂R⁶, or

R², R³, Y

and Z together with the nitrogen atom form a 3- to 8-membered saturated or unsaturated ring, which optionally can contain additional heteroatoms in the ring and optionally can be substituted in one or more places in the same way or differently with halogen, cyano, C₁-C₁₂-alkyl, C₁-C₁₂-alkoxy, halo-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl or with the group =O, -OR⁵, -SR⁴, -SOR⁴ or -SO₂R⁶,

R⁴ stands for C₁-C₆-alkyl, aryl or heteroaryl,

R⁵ stands for hydrogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₁₂-alkoxy, C₃-C₁₀-cycloalkyl or halo-C₃-C₆-cycloalkyl,

R⁶ stands for hydrogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, aryl or heteroaryl, or for the group -NR⁹R¹⁰, whereby the aryl or heteroaryl itself optionally can be substituted in one or more places in the same way or differently with C₁-C₆-alkyl, C₁-C₆-alkoxy, halogen or halo-C₁-C₆-alkoxy,

R⁷ and R⁸, independently of one another, stand for hydrogen or C₁-C₆-alkyl,

R⁹ and R¹⁰, independently of one another, stand for hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, aryl, C₃-C₈-cycloalkyl, or for the group -CONR⁷R⁸, or for C₁-C₆-alkyl that is optionally substituted in one or more places in the same way or differently with aryl, morpholino, hydroxy, halogen or C₁-C₁₂-alkoxy, or for the group -NR⁷R⁸, whereby the aryl itself optionally can be substituted in one or more places in the same way or differently with C₁-C₆-alkoxy or halo-C₁-C₆-alkyl, and

R¹¹ stands for C₁-C₆-alkyl, C₁-C₆-alkoxy, hydroxy-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, phenyl, pyridyl, biphenyl or naphthyl, whereby the phenyl itself can be substituted in one or more places in the same way or differently with C₁-C₆-alkyl, or halo-C₁-C₆-alkyl, as well as isomers, diastereomers, tautomers and salts thereof.

Claim 3 (Previously Presented): Compounds of general formula I, according to claim 1, in which

X stands for CH,

W stands for hydrogen,

A, B, D,

E, and Q as a ring together stand for pyridyl,

R¹ stands for phenyl, quinolinyl, isoquinolinyl or indazolyl, which optionally can be substituted in one or more places in the same way or differently with halogen, hydroxy, C₁-C₆-alkyl, C₂-C₆-alkinyl, C₁-C₆-alkoxy, halo-C₁-C₆-alkyl, or cyano-C₁-C₆-alkyl, whereby C₁-C₆-alkyl optionally also can be substituted with the group -OR⁵ or -NR⁹R¹⁰,

Y and Z, in each case independently of one another, stand for a bond, or for the group =CO,

R² and R³, independently of one another, stand for hydrogen or for the group -CONR⁹R¹⁰, -SO₂R⁶, -COR¹¹, -COC₁-C₆-alkyl, -CO-C₁-C₆-alkyl-R¹¹, -NR⁹R¹⁰ or for C₁-C₆-alkyl or phenyl that is optionally substituted in one or more places in the same way or differently with the group -NR⁷R⁸ or -OR⁵, or

R², R³, Y

and Z together with the nitrogen atom form a 3- to 8-membered saturated or unsaturated ring that optionally can contain additional heteroatoms in the ring and optionally can be substituted in one or more places in the same way or differently with halogen, cyano, C₁-C₁₂-alkyl, C₁-C₁₂-alkoxy, halo-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl or with the group =O, -OR⁵, -SR⁴, -SOR⁴ or -SO₂R⁶,

R⁵ stands for hydrogen or C₁-C₆-alkyl,

R⁶ stands for hydrogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, phenyl, benzyl,

thiophenyl, or pyridyl, whereby the phenyl, benzyl, thiophenyl and pyridyl itself optionally can be substituted in one or more places in the same way or differently with C₁-C₆-alkyl, C₁-C₆-alkoxy, halogen or halo-C₁-C₆-alkoxy,

R⁷ and R⁸, independently of one another, stand for hydrogen or C₁-C₆-alkyl,

R⁹ and R¹⁰, independently of one another, stand for hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, phenyl, biphenyl, C₃-C₈-cycloalkyl, naphthyl or for the group –CONR⁷R⁸ or for C₁-C₆-alkyl that is optionally substituted in one or more places in the same way or differently with phenyl, morpholino, hydroxy, halogen, C₁-C₁₂-alkoxy, or with the group –NR⁷R⁸, whereby the phenyl itself optionally can be substituted in one or more places in the same way or differently with C₁-C₆-alkoxy or halo-C₁-C₆-alkyl, and

R¹¹ stands for C₁-C₆-alkyl, C₁-C₆-alkoxy, hydroxy-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, phenyl, pyridyl, biphenyl or naphthyl, whereby the phenyl itself can be substituted in one or more places in the same way or differently with C₁-C₆-alkyl, or halo-C₁-C₆-alkyl, as well as isomers, diastereomers, tautomers and salts thereof.

Claim 4 (Currently Amended): Pharmaceutical agents ~~comprise~~ comprising at least one compound of general formula I and a pharmaceutically acceptable carrier.

Claim 5 (Original): Pharmaceutical agents according to claim 4 for use in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g., stent-induced

restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver, mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, inhibition of the reocclusion of vessels after balloon catheter treatment, vascular prosthetics or use of mechanical devices to keep vessels open, such as, e.g., stents, and as immunosuppressive agents, and for supporting scar-free healing, in senile keratosis and in contact dermatitis.

Claim 6 (Original): Pharmaceutical agents according to claim 5 for use as VEGFR kinase 3-inhibitors of lymphangiogenesis.


Claim 7 (Previously Presented): Compounds according to claim 1 and pharmaceutical agents, according to the present invention, with suitable formulations and vehicles.

Claim 8 (Currently Amended): ~~Use of the compounds of formula I, according to claim 1, as~~
A method of inhibitors of the inhibiting a tyrosine kinases kinase, KDR and or FLT, comprising
administering a compound of claim 1.


Claim 9 (Previously Presented): Use of the compounds of general formula I, according to claim 1, in the form of a pharmaceutical preparation for enteral, parenteral and oral administration.

Claim 10 (Currently Amended): ~~Use of the compounds according to claim 1 in the case of~~
A method of treating a tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such
as, e.g., stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia;
arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic
retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic
nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant
rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver, mesangial cell
proliferative diseases, arteriosclerosis, or injuries to nerve tissue, and for inhibiting the
reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical
devices are used to keep vessels open, such as, e.g., stents, and ~~as immunosuppressive agents for~~
immunosuppression, and for supporting scar-free healing, and ~~in to treat~~ senile keratosis ~~and in or~~
contact dermatitis.

Claim 11 (Original): Compounds of general formulas II, IIa, and III,



(II),



in which A, B, D, E, Q, W, X, Y, Z, R², and R³ have the meanings that are indicated in general formula I, and M stands for halogen, FG stands for a leaving group, such as, e.g., halogen, O-triflate, O-mesylate, O-tosylate or sulfone, and R^Y stands for C₁-C₆-alkyl or hydrogen, as intermediate products for the production of the compounds of general formula I according to the invention.